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Despite GPCRs sharing a common seven helix bundle, analysis of the diverse crystallographic structures available reveal
speciﬁc features that might be relevant for ligand design. Despite the number of crystallographic structures of GPCRs
steadily increasing, there are still challenges that hamper the availability of new structures. In the absence of a crystallo-
graphic structure, homology modeling remains one of the important techniques for constructing 3D models of proteins.
In the present study we investigated the use of molecular dynamics simulations for the reﬁnement of GPCRs models
constructed by homology modeling. Speciﬁcally, we investigated the relevance of template selection, ligand inclusion as
well as the length of the simulation on the quality of the GPCRs models constructed. For this purpose we chose the
crystallographic structure of the rat muscarinic M3 receptor as reference and constructed diverse atomistic models by
homology modeling, using different templates. Speciﬁcally, templates used in the present work include the human
muscarinic M2; the more distant human histamine H1 and the even more distant bovine rhodopsin as shown in the
GPCRs phylogenetic tree. We also investigated the use or not of a ligand in the reﬁnement process. Hence, we
conducted the reﬁnement process of the M3 model using the M2 muscarinic as template with tiotropium or NMS docked
in the orthosteric site and compared with the results obtained with a model reﬁned without any ligand bound.
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1. Introduction
G-protein-coupled receptors (GPCRs) belong to one of
the largest families of integral proteins in eukaryotic
organisms, being responsible for the primary mechanism
for signal transduction from the cell external environ-
ment to its cytoplasm. These receptors are activated by a
plethora of stimuli including different kinds of ligands,
like protein hormones, lipids, peptides, biogenic amines,
nucleotides, or ions and other exogenous stimuli like
light, odor, or taste. Agonists bind to receptor active
conformation that subsequently binds to a heterotrimeric
G-protein in the cytosol, resulting in inhibition or stimu-
lation of the production of second messengers that even-
tually elicit a cellular response (Katritch, Cherezov, &
Stevens, 2013; Kobilka, 2013). Interestingly, most of
these receptors exhibit a basal activity in the absence of
stimuli, suggesting that part of the receptors on the cell
surface are activated. Upon binding to these receptors,
ligands can act as agonists, antagonists, or inverse ago-
nists. The differential pharmacological proﬁle exerted by
GPCR ligands can be explained assuming that receptors
in a cell are in an ensemble of conformations, so that
agonists preferably bind to the active conformation,
whereas inverse agonists show more afﬁnity for the
resting conformation. Furthermore, antagonists exhibit
similar afﬁnity for both conformations and thus, do not
disturb the ensemble population, preventing both
agonists and inverse agonists to bind to the receptor.
Careful sequence alignments made using the trans-
membrane domain common to all GPCRs, permits to
classify this family of receptor into ﬁve main classes:
class A or rhodopsin-like, class B or secretin-like, class C
or metabotropic glutamate/pheromone, taste/frizzled-like
receptors and adhesion receptors (Schiöth & Fredriksson,
2005). Abnormalities of signaling by GPCRs are at the
root of disorders that affect most tissues and organs in our
body. Consequently, GPCRs are attractive targets for
therapeutic intervention with more than 30% of the
current drugs on the market (Overington, Al-Lazikani, &
Hopkins, 2006).
Early sequence analysis studies permitted to conclude
that GPCRs share a common architecture consisting of a
bundle of seven transmembrane α-helices (TM1–TM7)
connected by three intracellular loops (ICL1–ICL3) and
three extracellular loops (ECL1-ECL3). This common
architecture was subsequently conﬁrmed by X-ray
diffraction studies (Salon, Lodowski, & Palczewski,
2011). Presently, high-resolution structures of more than
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25 members of the rhodopsin-like family have been
solved bound to diverse ligands including biogenic ami-
nes, peptides, nucleosides, and a sphingolipids, providing
unprecedented insights into the structural and functional
diversity of these proteins (Shonberg, Kling, Gmeiner, &
Löber, 2015). Binding of agonists, inverse agonists, and
competitive antagonists to GPCRs occurs at the orthos-
teric site, a pocket located on the extracellular side of
the helix bundle that is highly conserved among the
members of a subfamily, although binding can be modu-
lated by residues located at the extracellular loops that
ﬂank the entrance. Moreover, analysis of the crystallo-
graphic structures available suggests that GPCRs are
very plastic and that different ligands can affect the
intrinsic dynamics of a receptor and activate distinct G
protein-mediated signaling pathways, a feature deﬁned as
‘functional selectivity’ (Rajagopal, Rajagopal, &
Lefkowitz, 2010). Interestingly, while residues deﬁning
the orthosteric binding site are well conserved within the
different GPCR subfamilies, those of the extracellular
loops are remarkably diverse within a subfamily, provid-
ing a good possibility to design selective allosteric
ligands (Rajagopal et al., 2010).
Despite the number of crystallographic structures of
GPCRs available having increased steadily in the last
few years, there are still challenges that hamper the
availability of novel structures including their low-ex-
pression yields, low receptor stability after detergent
extraction from native membranes, and high conforma-
tional heterogeneity (Ostermeier & Michel, 1997). In the
absence of crystallographic structures of many members
of the GPCR family, homology modeling can be used to
construct atomic resolution models that can be used: for
virtual screening studies; to accurately predict ligand
binding pockets; to study drug-receptor recognition as
well as the clariﬁcation of experimental data (Cutolo,
Basdevant, Bernadat, Bachelerie, & Ha-Duong, 2017;
Gandhimathi & Sowdhamini, 2016; Simms et al., 2009).
However, reliable modeling of GPCR-ligand complexes
for the vast majority of receptors with unknown structure
remains to be one of the most challenging goals for com-
puter-aided drug design (Spyrakis & Cavasotto, 2015).
The publication of the bovine rhodopsin structure at
atomic resolution provided for the ﬁrst time a template
to construct realistic models of GPCRs by homology
modeling (Palczewski et al., 2000). The structure has
been widely used as template to construct models of
diverse members of the rhodopsin-like family (Fanelli &
De Benedetti, 2011). Although sequence identity with
other GPCRs is small (about 20% on average), conserva-
tion of speciﬁc features among all the members of the
rhodopsin-like family provides support for considering
that there is a high structural similarity among members
of the family and consequently, for its use as template
(Bissantz, Logean, & Rognan, 2004). Despite its
successful use as template, its suitability as template to
accurately predict the structure of other GPCRs was soon
questioned (Archer, Maigret, Escrieut, Pradayrol, &
Fourmy, 2003). A critical point regards its low sequence
identity with other GPCRs and also, the high diversity of
ligand-binding features observed among different
GPCRs. The subsequent publication of the crystallo-
graphic structures of diverse ligand-infusible GPCR com-
plexes a few years later, made these drawbacks more
evident as inferred from the results of the diverse com-
munity-wide GPCR-Dock assessment competitions
(Kufareva, Katritch, Participants of GPCR Dock 2013,
Stevens, & Abagyan, 2014). In these studies it was
established a 35–40% sequence identity between target
and template as an empirical cutoff for reliable homol-
ogy-based prediction of ligand-receptor interactions. Pre-
sently, modeling approaches achieve close-to-
experimental accuracy for small rigid orthosteric ligands
when templates with high sequence identity are used
(Carlsson et al., 2011). However, there are still many
issues that need to be addressed to improve the quality
of the models constructed by homology modeling.
Diverse reports published recently address issues like
template selection (Costanzi et al., 2016; Latek, Pasznik,
Carlomagno, & Filipek, 2013; Mobarec, Sanchez, &
Filizola, 2009; Rataj, Witek, Mordalski, Kosciolek, &
Bojarski, 2014; Worth, Kleinau, & Krause, 2009; Zhu
& Li, 2012); inclusion of knowledge-based constraints
into the modeling process (Rodríguez, Ranganathan, &
Carlsson, 2014); modeling of the extracellular loops
(Goldfeld, Zhu, Beuming, & Friesner, 2013) and on
structure reﬁnement (Thomas et al., 2014).
In the present study, we investigated the use of
molecular dynamics (MD) simulations for the reﬁnement
of GPCRs models constructed by homology modeling
(Nowroozi & Shahlaei, 2017). Speciﬁcally, we investi-
gated the relevance of template selection, ligand inclu-
sion as well as the length of the simulation on the
quality of the GPCRs models constructed. For this pur-
pose, we chose the crystallographic structure of the rat
muscarinic M3 receptor as reference (Kruse et al., 2012)
and constructed diverse atomistic models by homology
modeling, using different templates. Speciﬁcally, tem-
plates used in the present work include the human mus-
carinic M2 (Haga et al., 2012); the more distant human
histamine H1 (Shimamura et al., 2011) and the even
more distant bovine rhodopsin (Palczewski et al., 2000)
as shown in the GPCRs phylogenetic tree. We also
investigated the use or not of a ligand in the reﬁnement
process. To that end we conducted the reﬁnement pro-
cess of the M3 model using the M2 muscarinic as tem-
plate with tiotropium or N-methylscopolamine (NMS)
docked in the orthosteric site and compared with the
results obtained with a model reﬁned without any ligand
bound. Preliminary results of this work have been
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already reported (Lupala, Rasaeifar, Gomez-Gutierrez, &
Perez, 2015; Martinez-Archundia, Cordomi, Garriga, &
Perez, 2012).
2. Methods
The procedure to construct atomistic models of GPCRs
by homology modeling involves the selection of a tem-
plate; target-template sequence alignment; construction
of a crude model and veriﬁcation; and model reﬁnement
(Cavasotto & Palomba, 2015; Nayeem, Sitkoff, & Krys-
tek, 2006). As mentioned above, homology models of
the rat muscarinic M3 receptor were constructed from
diverse templates using comparative modeling by means
of the Molecular Operating Environment (MOE) package
(2013.08; Chemical Computing Group ULC, Montreal,
QC, Canada). The sequence of the rat M3 muscarinic
receptor was retrieved from the Uniprot database (ID:
P08484), whereas for the diverse templates, we used the
sequences of the corresponding crystallographic struc-
tures, taking care of removing those residues correspond-
ing to the T4 Lysozyme inserted between TM5 and TM6
from the respective sequences, if applicable (PDB ID:
3UON for the human muscarinic M2; PDB ID: 3RZE
for the human histamine H1 and PDB ID: 1GZM for
bovine rhodopsin).
2.1. Model construction
Multiple sequence alignment of the sequences was car-
ried out using the MOE-Align tool (2013.08; Chemical
Computing Group ULC, Montreal, QC, Canada). Once
the alignment was completed and checked for unwanted
gaps within the TM region, we proceeded to construct
diverse atomistic models for each template. In order to
simplify the construction of the atomistic models of the
rat M3 receptor without compromising their accuracy,
the long intracellular loop (ICL3) was substituted by a
stretch of a few residues. Speciﬁcally, in the case of both
the M2 muscarinic and the histamine H1 receptors, since
both crystallographic structures correspond to fusion pro-
teins of the receptor with the T4-lysozyme inserted in
the ICL3, we simply removed the sequence of lysozyme
and joined the residues left. Thus, in the case of the M2
muscarinic receptor four residues from the C-terminus of
TM5 and seven residues from the N-terminus of TM6
and ﬁve residues from the C-terminus of TM5 and three
residues from the N-terminus of TM6 in the case of the
histamine H1 receptor. In the case of rhodopsin, we sim-
ply considered all residues of the corresponding ICL3.
Accordingly, diverse crude homology models for each of
the templates were constructed by threading the sequence
of the target receptor to each of the crystallographic
structures with the subsequent incorporation of alterna-
tive sidechain conformations using an extensive rotamer
library generated from a high-resolution structural data-
base embedded in MOE. Once hydrogens were added
using the protonate3D method (Labute, 2008), the crude
models were energy minimized using a contact energy
function to relieve any serious steric strains. The diverse
models generated for each template were scored accord-
ing to their rmsd to the average structure using the Cα
atoms for the calculation. The model with the highest
score was considered as a crude model and used for fur-
ther reﬁnement. Finally, the stereochemical quality of the
models constructed was assessed by the distribution of
the backbone dihedral angles in the Ramachandran map.
2.2. Molecular docking
Before proceeding the reﬁnement process, the antagonist
tiotropium (1) (Figure 1) co-crystallized in the rat mus-
carinic M3 receptor (PDB ID: 4DAJ) was docked onto
the orthosteric site of each of the three crude models,
using the GLIDE algorithm (Friesner et al., 2004). The
compound was docked in multiple orientations and mul-
tiple conformations. The resulted poses were rank
ordered by their binding/docking score using the glide-
score function. The best poses were analyzed visually
and validated in accordance to the information available
on the involvement of speciﬁc residues in binding from
diverse site directed mutagenesis studies (Blüml, Mutsch-
ler, & Wess, 1994; Han et al., 2005). Crude homology
models with tiotropium bound were used as starting
models for reﬁnement. In addition, in order to under-
stand the effect of using a ligand bound in the reﬁnement
process, two additional starting models for the M2 tem-
plate were constructed: one bound to the antagonist
NMS (2) (Figure 1) and another without any ligand
bound. Henceforth, four protein-ligand complexes of the
M3 muscarinic receptor and one without ligand were
reﬁned using molecular dynamic simulations.
2.3. Model reﬁnement
Models were reﬁned using MD simulations (Grossﬁeld,
2011; Sadiq et al., 2013). For each model, the starting
structure was embedded into a box of 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC) lipids and
water molecules previously equilibrated according to the
procedure described elsewhere (Cordomí, Edholm, &
Perez, 2007). The box had an initial size of
10.3 × 8.0 × 10.2 nm3 (XYZ), organized in such a way
that the bilayer plane was oriented on the XY plane.
Before protein insertion, the box contained 256 lipids
(corresponding to an area per lipid of 0.64 nm2) and circa
17,000 water molecules. The protein was placed in the
center of the box, and the overlapping molecules were
removed. Speciﬁcally, all water molecules with oxygen
atoms closer than 0.40 nm to a non-hydrogen atom of the
protein, as well as all lipid molecules with at least one
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atom closer than 0.25 nm to a non-hydrogen atom of the
protein were removed. This resulted in a ﬁnal system con-
taining 188 lipids and circa 14,655 water molecules.
Removal of these atoms introduced small voids between
the protein and water or lipid molecules that disappeared
during the ﬁrst part of the MD simulation, in which a pro-
gressive adjustment of the lipid bilayer and water mole-
cules to the protein takes place. Next, 105 randomly
selected water molecules were replaced by 45 sodium and
60 chloride ions, providing a neutral system with a con-
centration approximately 0.2 M on sodium chloride. This
concentration is fairly similar to that found in biological
organisms, although they exhibit different intra- and extra-
cellular ion concentrations.
For each model, a 500 ns MD simulation was carried
out at constant pressure using the GROMACS package
4.6 (Van Der Spoel et al., 2005). The all-atom OPLS
force ﬁeld (Kaminski, Friesner, Tirado-Rives, & Jor-
gensen, 2001) currently implemented in GROMACS,
was used to describe all molecules of the systems, except
for water that was modeled using the TIP3P model (Jor-
gensen, Chandrasekhar, Madura, Impey, & Klein, 1983).
The systems were subjected to periodic boundary condi-
tions in the three coordinate directions. The temperature
was kept constant at 300 K using separate thermostats
for the protein, water, ions and lipid molecules. The time
constant for the thermostats was set to 0.1 ps except for
water, for which a smaller value of 0.01 ps was used.
The pressure in the three coordinate directions was kept
at 0.1 MPa by independent Berendsen barostats using a
time constant of 1.0 ps. The equations of motion were
integrated using the leapfrog algorithm with a time step
of 2 fs. All bonds involving hydrogen atoms within the
protein and lipid molecules were kept frozen using the
LINCS algorithm (Miyamoto & Kollman, 1992). The
bonds and the angle of water molecules were ﬁxed using
the analytical SETTLE method. Lennard–Jones interac-
tions were computed using a cutoff of 1.0 nm. The elec-
trostatic interactions were treated either using the PME
technique (Essmann et al., 1995).
3. Results and Discussion
As mentioned above, the goal of the present study was
to investigate the performance of molecular dynamics
simulations used in the reﬁnement process. For this pur-
pose, we carried out a ‘semi-blind’ homology modeling
study of the rat M3 muscarinic receptor whose crystallo-
graphic structure is available, using the human M2 mus-
carinic receptor with and without an antagonist bound to
it, the human H1 histamine receptor and bovine rhodop-
sin as templates.
Sequence alignment of the rat muscarinic M3 receptor
with the human muscarinic M2, the human histamine H1,
and bovine rhodopsin shows sequence identities of 60, 34
and 17%, respectively (see Figure 2). These values are
larger if only the transmembrane (TM) regions are consid-
ered, with values of 79, 41, and 23%, respectively. Inter-
estingly, the best sequence identity score is found in the
TM3 segment, whereas the poorer is found in the TM1
segment in all the cases (Venkatakrishnan et al., 2013). As
in the rest of the muscarinic receptor subtypes, the intracel-
lular loop ICL3 of M3 is very long and was omitted for
modeling purposes. The deletion of this large segment
bears no consequences to the overall structure of the
GPCR or the orthosteric binding pocket as in the
muscarinic M3 receptor-phage T4 lysozyme fused protein
used for crystallographic studies where, receptor ability to
bind agonist or antagonist ligands is not modiﬁed.
As mentioned above, crude models were constructed
by threading the sequence of the target receptor on the
crystallographic structure of the templates with the sub-
sequent incorporation of the corresponding side chains
using a library of conformers. For each template alterna-
tive models were generated using template backbone
coordinates with alternative side chain conformations
using an extended rotamer library implemented in the
MOE package (2013.08; Chemical Computing Group
ULC, Montreal, QC, Canada). Following this process a
number of independent models, based on loop and side
chain placements were scored using a contact energy
function. Among these, the model with the highest score
Figure 1. Chemical structures of tiotropium (1) and N-methylscopolamine (NMS) (2).
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was selected for reﬁnement process. These crude models
presented similar distances to the target M3 crystallo-
graphic structure than the corresponding crystallographic
structures of the diverse templates. Thus, the muscarinic
M2 receptor exhibits a root-mean square deviation
(rmsd) 1.6 Å; 1.9 Å in the case of the histamine H1
receptor; and 2.3 Å in the case of rhodopsin (using the
backbone Cα for the measure).
An important drawback of the crude models con-
structed by homology modeling regards transmembrane
helix lengths. Residues involved in the diverse TMs, both
in the crude models and in the M3 crystallographic struc-
ture are listed in Table 1. As can be seen, for some of the
helices differences between the crude model and the M3
target structure are notorious. Thus, in the crude model
generated using M2 as template there are not large
differences. Important exceptions are TM3 that is seven
residues longer than the corresponding helix in the M3
crystallographic structure and TM6 that is ﬁve residues
longer. In contrast, crude models generated using the his-
tamine H1 and rhodopsin as templates show larger devia-
tions. Speciﬁcally, in the case of the H1 receptor TM1 is
ﬁve residues shorter; TM4 is eight residues longer and
TM6 is eleven residues longer, whereas the rest of the
helix segments have similar lengths. In the case of rhodop-
sin TM4 is six residues shorter, whereas TM5 is ﬁve resi-
due longer and TM2 and TM6 exhibit a three residue
difference. Taking into account that a α-helix contains 3.6
residues per turn, differences in helix length can sum up to
two turns.
Figure 2. Sequence alignment of the rat muscarinic M3 receptor (target) and the three templates (human muscarinic M2, human
histamine H1 and bovine rhodopsin) used in the present study. The transmembrane regions are shown in colors as TM1-TM7.
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3.1. The reﬁnement process
The reﬁnement process was aimed at relaxing the crude
model to capture speciﬁc structural features of the target
protein, not present in the template. As described in the
methods section, reﬁnement was carried out using MD
simulations of a system consisting of the target protein
embedded in a POCP lipid bilayer. The ﬁnal model of
the target receptors were produced from the average
structures computed of the last 50 ns of the respective
production runs, followed by energy minimization of the
protein structure using an effective dielectric constant of
2 to mimic the protein environment. This process was
carried out simply to eliminate possible crashes between
atoms found in the average structure.
In order for the reﬁnement process to be robust,
simulation times require to be long enough to ensure
that the system is equilibrated. System equilibration can
be monitored by the time evolution of the rmsd of the
successive trajectory snapshots in regard to the starting
structure. Figure 3(a) shows the rmsd time evolution
using the α-carbons of all residues for each of the simu-
lations performed in the present work. We also carried
out the same exercise considering only those residues
involved in the transmembrane domain (Figure 3(b)).
As can be seen, equilibration takes more than 200 ns of
simulation time. Comparison of the rmsd time evolution
between the whole protein and the transmembrane
domain suggests that there is a large contribution of the
loops to the high rmsd values observed. Moreover, anal-
ysis of Figure 3(a) and (b) clearly shows that during
the reﬁnement process, the initial structures suffer a
reorganization that is larger for those templates that are
more distant from the target receptor in the phylogenetic
tree, as expected. Thus, models of M3 constructed from
the M2 muscarinic receptor exhibit a rmsd of ~2.3 Å,
the model constructed from the histamine H1 receptor
exhibit a rmsd of ~2.7 Å and larger for the model con-
structed from rhodopsin that reaches ~3.0 Å. Another
interesting point inferred from the analysis of Figure 3(a)
and (b) is that those models reﬁned with a ligand
bound exhibit shorter equilibration times. This can be
clearly seen by looking at the rmsd time evolution of
the three models constructed using the M2 receptor as
template. The faster equilibration must be due to the
smaller ﬂexibility of the system expected when a ligand
is bound to the protein (Lin, Gether, & Kobilka, 1996).
These results agree with the use of ligands to model
active sites for in silico screening (Evers, Gohlke, &
Klebe, 2003).
The root-mean-square ﬂuctuations (rmsf ) of the
protein residues in the reﬁnement process are shown in
Figure 4(a) and (b). Speciﬁcally, Figure 4(a) shows the
ﬂuctuations per residue for each of the models along the
whole trajectory, whereas Figure 4(b) shows the ﬂuctua-
tions in the last 200 ns. Inspection of Figure 4(a) and (b)
reveals that the largest ﬂuctuations are associated with
the loops, as expected. Furthermore, comparison of the
two plots points to the large ﬂuctuations that occur
before equilibration, suggesting that they are basically
the result of loop rearrangement rather than actual
domain ﬂuctuations. For example, the EC1 and IC3
loops in rhodopsin show large ﬂuctuations at the begin-
ning of the reﬁnement process that disappears after
200 ns. Similar behavior is shown by loops EC1 and
EC2 in the model constructed from the H1 histamine
receptor. The evolution of the ﬂuctuations during the
reﬁnement process provides important information to
compute the average structure of the model.
Table 1. Amino acid segments involved in the diverse TM helices. The ﬁrst column regards the crystallographic M3 receptor,
whereas the rest of the columns correspond to the diverse homology models. In this case there are two entries for each TM helix: the
upper corresponds to the starting structure whereas the lower corresponds to the segment after reﬁnement.
Helix
M3 Crystal
structure M3M2 M3M2NMS
M3M2 with
Tiotropium
M3HRH1
withTiotropium
M3RHO
withTiotropium
TM1 W66 - V95 W66 - V95 W66 - V95 W66 - V95 F70 - K92 I64 - F93
W66 - V95 W66 - V95 W66 - V95 F70 - F93 V65 - F93
TM2 V102 - M131 V102 - M131 V102 - M131 V102 - M131 V102 - I130 I103 - I130
V102 - M131 V102 - M131 V102 - M131 V102 - I130 T101 - Y128
TM3 L139 - T171 G137 - Y176 G137 - Y176 G137 - Y176 G137 - Y176 N138 - I170
N138 - I170 N138 - T171 N138 - T171 A140 - T171 L139 - Y167
TM4 T182 - V211 T182 - V211 T182 - V211 T182 - V211 T182 - A203 T182 - L205
T182 - V211 T182 - V211 T182 - V211 K183 - Q208 R180 - W200
TM5 P229 - K256 P229 - K256 P229 - K256 P229 - K256 P229 - E257 E228 - K260
P229 - K256 P229 - K256 P229 - K256 P229 - E257 P229 - E259
TM6 L492 - T514 K488 - T515 K488 - T515 K488 - T515 I484 - C517 A489 - T514
A490 - T515 Q491 - T515 Q491 - T515 K488 - C517 I484 - T514
TM7 K522 - C546 K522 - C546 K522 - C546 K522 - C546 K522 - C546 K522 - C546
K522 - C546 K522 - C546 K522 - C546 K522 - C546 K522 - C546
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In regard to the transmembrane domain, it is very
encouraging to observe that the reﬁnement process is
able to correct the length of the TM helices. Table 1 lists
the amino acids involved in the diverse TM helices both
in the crystallographic M3 receptor and in the diverse
models. In this latter case for each TM helix there are
two entries: the upper corresponds to the starting model,
whereas the lower corresponds to the TM helix after the
reﬁnement process. As shown in Table 1, in the case of
the models constructed using the M2 as template, both
TM3 and TM6 are longer than in the crystallographic
structure of the target receptor, however during the
reﬁnement process the length of the helices is shortened,
providing a model that is only one residue longer that in
the crystallographic structure. In the case of the model
constructed from the histamine H1 receptor TM1, TM3
and TM6 are longer than the crystallographic structure
of the target receptor, whereas TM4 is shorter. As can be
seen from Table 1, except for the TM1 the reﬁnement
process is capable to modify helix length accordingly. In
the case of the model constructed from rhodopsin TM4
is shorter and TM6 longer than the target crystallo-
graphic structure. Unfortunately, in this case the reﬁne-
ment process is not capable to get the right length for
these two segments.
A key point for assessing the performance of
the reﬁnement process is to monitor the improvement
of the model from the starting structure. Figure 5
displays the time evolution of the rmsd of the models
compared to the crystallographic structure of the
muscarinic M3 receptor, using the Cα of the residues that
belong to transmembrane region. Inspection of Figure 5
Figure 3. Time evolution of the rmsd of the diverse models studied in the present work from their respective starting structures
along the reﬁnement process. (a) rmsd computed using the Cα of all the residues of the protein; (b) rmsd computed using the Cα of
the residues of the transmembrane domain.
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suggests that in general, the rmsd decreases during the
reﬁnement process with a consequent net improvement
of the structures. Speciﬁcally, after the 500 ns the model
constructed using rhodopsin as template shows an
improvement from 4.8 Å to 4.3 Å; for the model built
from the histamine there is not a net improvement;
whereas, for the models constructed from the muscarinic
M2 there is an improvement from 2.5 Å to 2.3 Å for the
case that the model was constructed without ligand and
smaller, from 2.0 Å to 1.8 Å for the model reﬁned using
NMS as ligand and, from 1.8 Å to 1.5 Å for the model
constructed with tiotropium. In contrast, the rmsd using
the whole protein (data not shown) does not show a net
improvement in the reﬁnement process due to the ﬂuctu-
ations of the loops.
In regard to the loops, the beneﬁts of the reﬁnement
process are not so obvious. Thus, present results once
more suggest that the accuracy of the loops obtained
after the reﬁnement process depends on the distance
between the template and the target in the phylogenetic
tree. However, the large ﬂuctuations experienced by
loops during the MD simulation tend to produce average
structures that despite capturing the features of the target
structure are not very accurate. Speciﬁcally, present
results suggest that when the initial structure is close to
the target, loops are worsened after the reﬁnement
process. In contrast, when the initial structure is far from
the target, loops are improved after the reﬁnement pro-
cess. Figures 6 and 7 show the superimposition of the
ECL2 and the ICL2 loops, respectively, for the diverse
models studied in the present study before and after the
reﬁnement process. Inspection of Figure 6(a) shows for
those models constructed using the M2 muscarinic recep-
tor the ECL2 loop is well superimposed to that of the
target M3 muscarinic receptor, whereas in the case of the
models constructed using the histamine H1 and rhodop-
sin receptors large deviations are obvious. However, after
reﬁnement (Figure 6(b)) models constructed using the
M2 muscarinic receptor show the loops with the features
of the target receptor but with small deviations. In
Figure 4. Root mean square ﬂuctuations (rmsf) per residue of the diverse models computed along the reﬁnement process. (a) rmsf
computed along the whole reﬁnements process. (b) rmsf obtained during the last 200 ns of the reﬁnement process.
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contrast, the loops of the models constructed using the
histamine H1 and rhodopsin show a modest improve-
ment in regard to the starting structure. The same trends
can be deduced from the analysis of the ICL2
(Figure 7(a) and (b)). Speciﬁcally, for the models con-
structed using the M2 muscarinic receptor as template,
the loop of the initial models exhibits a helical structure
that superimposes well in the target structure, but shows
deviations after the reﬁnement process. In contrast, in
the models constructed using the histamine H1 and rho-
dopsin the loop does not exhibit any secondary structure
in the initial models, but it is captured after reﬁnement.
In view of these results, it can be concluded that the
large ﬂuctuations suffered by the loops in the reﬁnement
process worsen the structure of the loops when the
template and the target are close although the structural
Figure 5. Time evolution of the rmsd of the diverse homology models from the target crystallographic structure computed using the
Cα of the residues of the transmembrane domain.
Figure 6. Superposition of the ECL2 loop corresponding to the ﬁve models studied in the present work. (a) Before the reﬁnement
process. (b) After the reﬁnement process. In Green is the rat M3 crystal structure; in cyan the M2 template-tiotropium model; in
magenta the M2 template-NMS model; in dark blue the M2 template without ligand model; in orange the histamine template-tiotro-
pium model; and in red the rhodopsin template-tiotropium model.
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features are preserved. In contrast, when the template is
far from the target the structures are improved, although
longer sampling times are presumably required.
3.2. Analysis of the homology models constructed
As expected, the models constructed using the M2 mus-
carinic receptor as template, are closer to the target struc-
ture. Values of the rmsd of the diverse models
constructed using the human muscarinic M2 receptor
(using backbone Cα) are: 1.9 Å for the model reﬁned
with no ligand bound; 2.4 Å for the model constructed
with tiotropium bound and 2.5 Å for the model con-
structed with NMS bound. However, the relative high
rmsd values are due to the loops. The models are able to
capture small rearrangements of the TM1 N-terminus
segment; TM5 C-terminal segment, as well as TM7 mid-
dle segment toward the interior of the helix bundle,
shown in the comparison of the M2 and M3 crystallo-
graphic structures (Kruse et al., 2012). Despite these
rearrangements, there are certain features associated with
the loops that are present in the starting models and are
lost during the reﬁnement process. Speciﬁcally, the pro-
nounced outward bend at the extracellular end in TM4,
found in the crystallographic structures of the M2 and
M3 muscarinic receptors (Kow & Nathanson, 2012) is
preserved in the models constructed with tiotropium or
NMS, but lost in the model constructed without any
ligand.
The model of the muscarinic M3 constructed using
the histamine H1 receptor bound to tiotropium yields an
rmsd of 3.2 Å compared to the reference crystallographic
structure. Comparison of the two structures reveals
differences between the modeled and the crystallographic
structure, being the largest difference found at the C-ter-
minus of TM4. In this model both the ECL2 and ICL2
loops do not accommodate well to the space shown by
the models constructed using the muscarinic M2 recep-
tor, although it can be seen certain improvement in
regard to the initial structures (see Figures 6 and 7).
Regarding the length of the TM segments, the reﬁnement
process reduces slightly the differences found in the
starting structure (see Table 1), but are not completely
resolved. Speciﬁcally, TM1 is six residues shorter; TM2
and TM3 are one residue shorter; TM4 is in the ﬁnal
model four residues shorter catching up partly to the
eight residues shorter of the starting model. Contrast-
ingly, TM5 remains one residue longer while TM6 is
seven residues longer correcting in part the eleven
residues of the starting structure and TM8 remains one
residue shorter.
Finally, the model of the muscarinic M3 receptor
constructed using the rhodopsin bound to tiotropium
yields a rmsd with the crystallographic structure of 4.79
Å similar to the starting model, suggesting that little
improvement has been achieved during the reﬁnement
process. Comparison of the two structures reveals large
differences between the modeled and the crystallographic
structure. On the one hand, like in the model constructed
using the histamine H1 receptor both the ECL2 and
ICL2 loops do not accommodate well to the space
shown by the models constructed using the muscarinic
M2 receptor and only a small improvement can be seen
in regard to the initial structures (see Figures 6 and 7).
In regard to the length of the TM segments the reﬁne-
ment process reduces slightly the differences found in
Figure 7. Superposition of the ICL2 loop corresponding to the ﬁve models studied in the present work. (a) Before the reﬁnement
process. (b) After the reﬁnement process. In Green is the rat M3 crystal structure; in cyan the M2 template-tiotropium model; in
magenta the M2 template-NMS model; in dark blue the M2 template without ligand model; in orange the histamine template -tiotro-
pium model; and in red the rhodopsin template-tiotropium model.
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the staring structure (see Table 1), but differences are
still remarkable. Speciﬁcally, TM2 is one residue shorter;
TM3 is four residues shorter; TM4 is thirteen residues
shorter worsening the starting model; TM5 is remains
one residue longer and TM6 is nine residues longer.
Finally, in order to understand the utility of the mod-
els generated for docking studies, we docked tiotropium
onto the diverse models before and after being subjected
to the reﬁnement process. The crystallographic structure
of tiotropium bound to the muscarinic M3 receptor
shows the ligand sitting in a pocket conformed by
helices TM3, MT5, TM6 and TM7. It is oriented in such
a way that the ligand shows the tiophene groups in the
proximity of TM5, whereas the quaternary nitrogen is
ﬂanked by TM3 and TM7. The ligand exhibits diverse
interactions with the neighboring residues: the quaternary
nitrogen sits close to Asp147; Asn507 forms two polar
interactions with the carbonyl and with the hydroxyl
groups of tiotropium, respectively; the epoxy group exhi-
bits an interaction with the sidechain of Ser152 and one
of the tiophene groups sits at interacting distance with
Trp504 (Kruse et al., 2012). All the models described in
the present work are capable to reproduce the pose tio-
tropium adopts when bound to the M3 receptor. How-
ever, in regard to the diverse interactions with the
sidechains of the neighboring residues, most of the initial
structures fulﬁll only part the set of ligand-receptor inter-
actions found in the crystal, however after reﬁnement all
the structures fulﬁll all the features of the crystallo-
graphic structure.
4. Conclusions
The aim of the present work was to assess the perfor-
mance of molecular dynamics simulations of the receptor
embedded in a lipid bilayer for the purpose of reﬁning
homology models of GPCRs. Speciﬁcally, several
homology models of the rat muscarinic M3 receptor
whose crystallographic structure is known were
constructed using diverse templates located at diverse
distances on the phylogenetic tree. Speciﬁcally, templates
used in the present work include the human muscarinic
M2 receptor; the human histamine receptor H1 and
bovine rhodopsin. We also investigated the effect of
using a ligand bound to the orthosteric site on the perfor-
mance of the reﬁning process. For this purpose we also
constructed models of the rat muscarinic M3 receptor
using the human M2 muscarinic receptor without ligand
and with tiothropium and NMS bound. The study reveals
that these systems achieve equilibration after more than
250 ns of simulation, although if only the transmembrane
region is considered equilibration is achieved much fas-
ter. Present results show that the use of molecular
dynamics improves the quality of the homology models
mostly on the transmembrane region. Speciﬁcally, the
reﬁnement process permits the correction of the length
of the helices and improves the accuracy of the helix
bundle. Despite the constructed models capturing most
of the features of the M3 receptor, the distance in the
phylogenetic tree affects their quality, being the most
accurate models those constructed using a template close
to the target receptor. Accordingly, the reﬁnement pro-
cess as performed in this work is not powerful enough
to correct the starting model when the chosen template is
distant from the target. Moreover, inclusion of a ligand
on the modeling makes the reﬁnement more robust since
equilibration is observed faster.
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